Clinical Trials Logo

Clinical Trial Summary

To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04413344
Study type Interventional
Source Kyoto University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 5, 2020
Completion date November 15, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03657732 - The Chinese Familial Alzheimer's Network
Recruiting NCT03653156 - China Cognition and Aging Study